AstraZeneca Targets $80 Billion Revenue by 2030 Through Pipeline Expansion
By Helena Smolak
AstraZeneca has set out a target to grow revenue to $80 billion by 2030 as it aims to bolster its investment in technologies and platforms.
In a statement ahead of its investor day Tuesday the Anglo-Swedish pharmaceutical giant said it to will develop 20 new medicines throughout the next six years and expects significant growth across all its therapy areas.
To deliver its revenue target, the company aims for a mid-30s percentage core operating margin by 2026. Beyond 2026, core operating margin will be influenced by its portfolio evolution, targeting at least the mid-30s percentage range, it said.
AstraZeneca expects sustained growth post 2030.
The company generated revenue of $45.81 billion last year and core earnings per share--its preferred metric--of $7.26.
Last month the company reported an increased performance for its key metrics and reiterated its full-year guidance.
Revenue for the quarter rose 19% to $12.68 billion while its core EPS increased 13% to $2.06.
AstraZeneca expects revenue and core EPS for the year to grow by low double-digit to low teens percentage.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 21, 2024 02:32 ET (06:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued